Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026 ...
Dish,” to test anti-amyloid therapies. The approach has already been used to screen thousands of compounds and enables more ...
More than 80% of no-option chronic limb-threatening ischemia patients avoided amputation for 6 months after the procedure ...
NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered ...
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both ...
RBM20 truncating variants ( RBM20 tvs) appear to contribute to arrhythmogenic dilated cardiomyopathy (DCM) but with ...
Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.
THE campaign to promote the adoption of electric vehicles (EVs) as an alternative to internal combustion engine (ICE) cars is ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration ...
Researchers demonstrated that self-administered fingerprick blood tests measuring p-tau217 and GFAP, returned by post, ...
An at-home, mail-in, finger-stick blood test detected Alzheimer’s-related biomarkers associated with cognitive performance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results